<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03272412</url>
  </required_header>
  <id_info>
    <org_study_id>1704-VLC-024-EL</org_study_id>
    <nct_id>NCT03272412</nct_id>
  </id_info>
  <brief_title>Serum Progesterone on the Day of Embryo Transfer and Pregnancy Rate.</brief_title>
  <official_title>Impact of Serum Progesterone Levels on the Day of Embryo Transfer in Artificial Endometrial Preparation Cycles on the Ongoing Pregnancy Rate.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Valenciano de Infertilidad, IVI VALENCIA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Valenciano de Infertilidad, IVI VALENCIA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to analyze whether serum Progsterone levels on the day of Embryo Transfer are
      related with Ongoing Pregnancy rate in artificial endometrial preparation cycles with
      intravaginal micronized progesterone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 8, 2017</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of serum Progesterone levels</measure>
    <time_frame>The day of embryo transfer</time_frame>
    <description>Serum progesterone levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ongoing Pregnancies depending on Progesterone levels ranges.</measure>
    <time_frame>Week 5-12 after Embryo Transfer</time_frame>
    <description>Ultrasound to confirm Ongoing Pregnancy</description>
  </primary_outcome>
  <enrollment type="Anticipated">1197</enrollment>
  <condition>Ongoing Pregnancy Rate</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Analysis of serum Progesterone in blood sample</intervention_name>
    <description>Levels of progesterone will be determined on the day of embryo transfer in patients undergoing artificial endometrial preparation cycles.</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women who are undergoing IVF treatments with artificial endometrial preparation with
        hormonal replacement therapy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Age &lt;50 years old

          2. Hormonal Replacement therapy cycle for embryo transfer in any of the following
             situations:

               1. Embryos in fresh cycle with donated oocytes.

               2. Subsequent embryo transfers of vitrified embryos in cycles of donated oocytes.

               3. Frozen embryo transfers in cycles with autologous oocytes.

          3. Endometrial line: &gt;6.5-7mm (with trilaminar aspect) in proliferative phase, before
             introducing progesterone.

          4. Administration of natural micronized progesterone intravaginally (400 mg/12 hours for
             5 complete days (10 dosis), before the embryo transfer and maintained until pregnancy
             week 12.

          5. Embryo transfer of blastocyst (day 5-6).

          6. Signed Informed Consent

        Exclusion Criteria

          1. Uterine pathology (submucous o intramural fibroids (&gt;4 cm) or which deform the uterine
             cavity; endometrial polyps or MÃ¼llerian anomalies; or adnexal anomalies (communicating
             hydrosalpinx).

          2. Simultaneous participation in another clinical study.

          3. Participation in another clinical study before the inclusion in the present study, and
             which could affect the objectives of the present study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elena Labarta, MD PhD</last_name>
    <phone>34963050900</phone>
    <email>elena.labarta@ivi.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Caracena, MA</last_name>
    <phone>963050925</phone>
    <email>laura.caracena@ivi.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Valenciano de Infertilidad Spain</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Labarta, MD PhD</last_name>
      <phone>34 96 3050900</phone>
      <email>elena.labarta@ivi.es</email>
    </contact>
    <contact_backup>
      <last_name>Laura Caracena, MA</last_name>
      <phone>963050925</phone>
      <email>laura.caracena@ivi.es</email>
    </contact_backup>
    <investigator>
      <last_name>Elena Labarta, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2017</study_first_submitted>
  <study_first_submitted_qc>September 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2017</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Valenciano de Infertilidad, IVI VALENCIA</investigator_affiliation>
    <investigator_full_name>Elena Labarta</investigator_full_name>
    <investigator_title>Gynecologist IVI Valencia</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

